1. Home
  2. KRRO vs RDIB Comparison

KRRO vs RDIB Comparison

Compare KRRO & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$13.29

Market Cap

187.9M

Sector

Health Care

ML Signal

HOLD

Logo Reading International Inc Class B

RDIB

Reading International Inc Class B

HOLD

Current Price

$9.00

Market Cap

204.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRRO
RDIB
Founded
2014
1937
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
187.9M
204.5M
IPO Year
2019
1994

Fundamental Metrics

Financial Performance
Metric
KRRO
RDIB
Price
$13.29
$9.00
Analyst Decision
Buy
Analyst Count
12
0
Target Price
$34.80
N/A
AVG Volume (30 Days)
128.3K
11.6K
Earning Date
05-13-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.76
EPS
N/A
N/A
Revenue
$6,392,000.00
$202,988,000.00
Revenue This Year
N/A
$16.25
Revenue Next Year
N/A
$4.04
P/E Ratio
N/A
N/A
Revenue Growth
181.46
N/A
52 Week Low
$5.20
$8.01
52 Week High
$55.89
$17.40

Technical Indicators

Market Signals
Indicator
KRRO
RDIB
Relative Strength Index (RSI) 60.71 50.77
Support Level $9.76 $8.49
Resistance Level $14.53 $10.50
Average True Range (ATR) 0.78 0.35
MACD 0.32 0.04
Stochastic Oscillator 83.25 47.37

Price Performance

Historical Comparison
KRRO
RDIB

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

About RDIB Reading International Inc Class B

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: